Literature DB >> 11590628

Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation.

I R White1, C Bamias, P Hardy, S Pocock, J Warner.   

Abstract

Patients in some randomized clinical trials may start additional non-randomized medication because of an exacerbation of symptoms or insufficient therapeutic effect. Typically this rescue medication reduces the observed treatment effect in intention-to-treat analysis. We discuss methods of analysis which take account of rescue medication in order to achieve a more meaningful comparison of the randomized treatments, focusing on trials with a repeated quantitative outcome. Ignoring all data after rescue is likely to be biased because rescued patients are a highly selected group. Instead we propose using methods based on ranks or multilevel models. The rank-based methods assume that rescued patients have especially bad underlying outcomes. The multilevel regression model relates a patient's outcome to allocated treatment and rescue status at each time, and requires correct modelling of all prognostic factors which predict starting rescue medication and of the covariance between outcomes measured at different times. We also describe sensitivity analyses over a range of possible models for the effect of rescue medication. We illustrate these methods in a trial in Parkinson's disease. It appears that adjustment for rescue medication will not radically alter the randomized treatment comparison unless rescue medication is substantially imbalanced between randomized groups and has a substantial effect on the outcome. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590628     DOI: 10.1002/sim.927

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  Clinical effectiveness and micro-perfusion alteration of Jingui external lotion in patients with knee osteoarthritis: study protocol for a randomized controlled trial.

Authors:  Da Guo; Xue-Wei Cao; Jin-Wen Liu; Wei Niu; Zhen-Wei Ma; Ding-Kun Lin; Jia-Yi Chen; Wei-Dong Lian; Wen-Wei Ouyang; Jun Liu
Journal:  Trials       Date:  2015-03-28       Impact factor: 2.279

2.  The efficacy and safety of the Shaoyao Shujin tablet for knee osteoarthritis: study protocol for a randomized controlled trial.

Authors:  Xue-Wei Cao; Da Guo; Jin-Wen Liu; Wei Niu; Jun Liu; Jian-Ke Pan; Hui Xie; Wen-Wei Ouyang; Ding-Kun Lin
Journal:  Trials       Date:  2016-01-04       Impact factor: 2.279

Review 3.  Current approaches to handling rescue medication in asthma and eczema randomized controlled trials are inadequate: a systematic review.

Authors:  Anca Maria Chis Ster; Victoria Cornelius; Suzie Cro
Journal:  J Clin Epidemiol       Date:  2020-06-03       Impact factor: 6.437

4.  Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trials.

Authors:  Kathy Y Liu; Anya Borissova; Jansher Mahmood; Thomas Elliott; Melanie Knowles; Peter Bentham; Suzanne Reeves; Robert Howard
Journal:  Alzheimers Dement (N Y)       Date:  2021-03-30

5.  Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Authors:  Michael A Nauck; Murray W Stewart; Christopher Perkins; Angela Jones-Leone; Fred Yang; Caroline Perry; Rickey R Reinhardt; Marc Rendell
Journal:  Diabetologia       Date:  2015-11-17       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.